Why Axia Medicine? A reflection on connecting patients with researchers and Personalised Healthcare service providers.
It's always great to catch up with literature, especially for topics close to Axia Medicine [SEIS] customer needs.
When I started my career, Roche 454 was the future. Then came the promising underdog, Illumina, whose team's exceptional vision and talent has been dominating the "Omics" industry for more than a decade.
That foundation has turned Precision Medicine from an aspiration to a global industry.
Clinical applications of sequencing have started seeing more of Oxford Nanopore Technologies long reads, hashtag#proteomics, hashtag#singlecell and other assays. Still , our industry has been held back by the lack of real population-scale Omics infrastructure.
In particular integration of heterogeneous, highly-dimensional multi-omics data with a patient's profile stands out as a top opportunity and challenge - for the industry, and for each patient.
Axia Medicine was conceived with a multi-omics industry in mind, to enable each patient and each biopharma to make the most of Omics technology, without having to compromise Health AI innovation.
By bringing together patients, researchers and service providers, our platform minimises the friction in finding, accessing and leveraging multi-omics datasets, at population scale.
The opportunity is huge, and our initial customer conversations confirms our vision and roadmap are best positioned to make the promise of personalized medicine a tangible reality.
Every piece of data brings us closer to groundbreaking discoveries and treatments:
Personalised Healthcare Starts With You.
#PrecisionMedicine #MultiOmics #CancerResearch #AxiaMedicine #InnovationInHealthcare #fundraising #seis
